Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT

Dian, Lulu; Xu, Zhiguang; Sun, Yanfang; Li, Jinhua; Lu, Hongfei; zheng, Meng; Wang, Juan; Дробот, Л. Б.; Horak, I. R.

doi:10.1016/j.phytochem.2022.113217

Cited by 24 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ZO-1 was found to be activated by BBR, which lead to enhancing the binding of ZO-1 and the cyclin-dependent kinase 4 (CDK4) and reducing CDK4 entry into the nucleus (68,69). Then, the free Wnt/b-catenin level was also downregulated, which suppresses cancer cell proliferation via induced cell cycle arrest (70,71). The present study also demonstrated that BBR inhibited the proliferation and migration of BC cells partially via inactivating the ZO-1-mediated Wnt/b-catenin signaling pathway.…”

Section: Dna Tata Box and Poly(a) Tailssupporting

confidence: 61%

Berberine as a potential agent for breast cancer therapy

Zhong

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer (BC) is a common malignancy that mainly occurred in women and it has become the most diagnosed cancer annually since 2020. Berberine (BBR), an alkaloid extracted from the Berberidacea family, has been found with broad pharmacological bioactivities including anti-inflammatory, anti-diabetic, anti-hypertensive, anti-obesity, antidepressant, and anticancer effects. Mounting evidence shows that BBR is a safe and effective agent with good anticancer activity against BC. However, its detailed underlying mechanism in BC treatment remains unclear. Here, we will provide the evidence for BBR in BC therapy and summarize its potential mechanisms. This review briefly introduces the source, metabolism, and biological function of BBR and emphasizes the therapeutic effects of BBR against BC via directly interacting with effector proteins, transcriptional regulatory elements, miRNA, and several BBR-mediated signaling pathways. Moreover, the novel BBR-based therapeutic strategies against BC improve biocompatibility and water solubility, and the efficacies of BBR are also briefly discussed. Finally, the status of BBR in BC treatment and future research directions is also prospected.

show abstract

Section: Dna Tata Box and Poly(a) Tailssupporting

confidence: 61%

Berberine as a potential agent for breast cancer therapy

Zhong

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…98). Berberine inhibited Wnt/ β -catenin signalling in breast cancer cells by decreasing β -catenin expression and increasing GSK3 β expression, thereby inhibiting the EMT process in MDA-MB-231 and MCF-7 breast cancer cell lines, resulting in a decrease in metastatic and invasive properties (Refs 99, 100).…”

Section: Research Progress Of Alkaloids Extracted From Traditional Ch...mentioning

confidence: 99%

Wnt/β-catenin signalling pathway in breast cancer cells and its effect on reversing tumour drug resistance by alkaloids extracted from traditional Chinese medicine

Lin

Mao

et al. 2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Breast cancer is a high-risk disease with a high mortality rate among women. Chemotherapy plays an important role in the treatment of breast cancer. However, chemotherapy eventually results in tumours that are resistant to drugs. In recent years, many studies have revealed that the activation of Wnt/β-catenin signalling is crucial for the emergence and growth of breast tumours as well as the development of drug resistance. Additionally, drugs that target this pathway can reverse drug resistance in breast cancer therapy. Traditional Chinese medicine has the properties of multi-target and tenderness. Therefore, integrating traditional Chinese medicine and modern medicine into chemotherapy provides a new strategy for reversing the drug resistance of breast tumours. This paper mainly reviews the possible mechanism of Wnt/β-catenin in promoting the process of breast tumour drug resistance, and the progress of alkaloids extracted from traditional Chinese medicine in the targeting of this pathway in order to reverse the drug resistance of breast cancer.

show abstract

“…Gao et al, 2022), SIN3 transcription regulator family memberA/topoisomerase (DNA) II alpha pathway (J. Chen et al, 2020), mTOR pathway (Kumar et al, 2020), and wingless/β-catenin pathway (Dian et al, 2022). It was reported that BBR played a vital role acute lung injury and Covid-19 via its anti-inflammation activity (Babalghith et al, 2022).…”

Section: Berberine (Bbr) Is the Main Component Isolated From Coptidismentioning

confidence: 99%

“…Recently, increasing evidence demonstrated that there was a broad panel of target genes of BBR in multiple cancers, like elevating the sensitivity of ovarian cancer cells to PARP inhibition (Hou et al, 2017), targeting Ephrin‐B2 to suppress the growth and metastasis of breast cancer cells (Ma et al, 2017), and upregulating miR‐19a to induce apoptosis in NSCLC (Q. Q. Chen et al, 2019). Multiple research have displayed that BBR prevented cancer progression mainly via regulating some signaling pathways, such as januskinase2/signal transducer and activator of transcription3 pathway (Xu et al, 2022), phosphatidylinositol‐3‐kinase/protein kinase B (PI3K/AKT) pathway (X. Gao et al, 2022), SIN3 transcription regulator family memberA/topoisomerase (DNA) II alpha pathway (J. Chen et al, 2020), mTOR pathway (Kumar et al, 2020), and wingless/β‐catenin pathway (Dian et al, 2022). It was reported that BBR played a vital role acute lung injury and Covid‐19 via its anti‐inflammation activity (Babalghith et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway

Wang

Hua

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

BackgroundNonsmall cell lung cancer (NSCLC) is the main type of lung cancer, accounting for approximately 85%. Berberine (BBR), a commonly used traditional Chinese medicine, has been reported to exhibit a potential antitumor effect in various cancers. In this research, we explored the function of BBR and its underlying mechanisms in the development of NSCLC.MethodsCell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐20‐deoxyuridine (EdU), colony formation assays, flow cytometry, and transwell invasion assay were employed to determine cell growth, the apoptotic rate, cell invasion of NSCLC cells, respectively. Western blot was applied for detecting the protein expression of c‐Myc, matrix metalloprotease 9 (MMP9), kinesin family member 20A (KIF20A), cyclin E2 (CCNE2), and phosphatidylinositol‐3‐kinase/protein kinase B (PI3K/AKT) pathway‐related proteins. Glycolysis was evaluated by detecting glucose consumption, lactate production, and adenosine triphosphate/adenosine diphosphate (ATP/ADP) ratio with the matched kits. Real‐time quantitative polymerase chain reaction (RT‐qPCR) was conducted to analyze the level of KIF20A and CCNE2. Tumor model was established to evaluate the function of BBR on tumor growth in NSCLC in vivo. In addition, immunohistochemistry assay was employed to detect the level of KIF20A, CCNE2, c‐Myc, and MMP9 in mice tissues.ResultsBBR exhibited suppressive effects on the progression of NSCLC, as evidenced by inhibiting cell growth, invasion, glycolysis, and facilitating cell apoptosis in H1299 and A549 cells. KIF20A and CCNE2 were upregulated in NSCLC tissues and cells. Moreover, BBR treatment significantly decreased the expression of KIF20A and CCNE2. KIF20A or CCNE2 downregulation could repress cell proliferation, invasion, glycolysis, and induce cell apoptosis in both H1299 and A549 cells. The inhibition effects of BBR treatment on cell proliferation, invasion, glycolysis, and promotion effect on cell apoptosis were rescued by KIF20A or CCNE2 overexpression in NSCLC cells. The inactivation of PI3K/AKT pathway caused by BBR treatment in H1299 and A549 cells was restored by KIF20A or CCNE2 upregulation. In vivo experiments also demonstrated that BBR treatment could repress tumor growth by regulating KIF20A and CCNE2 and inactivating the PI3K/AKT pathway.ConclusionBBR treatment showed the suppressive impact on the progression of NSCLC by targeting KIF20A and CCNE2, thereby inhibiting the activation of the PI3K/AKT pathway.

show abstract

Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT

Cited by 24 publications

References 25 publications

Berberine as a potential agent for breast cancer therapy

Berberine as a potential agent for breast cancer therapy

Wnt/β-catenin signalling pathway in breast cancer cells and its effect on reversing tumour drug resistance by alkaloids extracted from traditional Chinese medicine

Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway

Contact Info

Product

Resources

About